5-Amino-1MQ Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is 5-Amino-1MQ?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Metabolic regulation, fat oxidation, obesity models, muscle regeneration, cellular energy, hepatic steatosis, glucose homeostasis
• First Characterized: 2017
• Molecular Weight: 159.21 g/mol (free base); 286.11 g/mol (iodide salt)
• Research Status: 30+ published preclinical studies; no human Phase II or Phase III clinical trials
• Key Mechanisms: NNMT inhibition, NAD+ preservation and elevation, SIRT1 activation, PGC-1alpha pathway stimulation
• Published Studies: Diet-induced obesity mouse models, aged muscle regeneration studies, hepatic steatosis models, in vitro adipocyte and cancer cell studies
• Clinical Trial Status: No human clinical trials registered or published as of current literature
• Regulatory Classification: Research use only; not approved for human therapeutic use by FDA or equivalent international bodies
• CAS Number: 42464-96-0
• PubChem CID: 950107

What is 5-Amino-1MQ?

5-Amino-1MQ, formally named 5-amino-1-methylquinolinium, is a small molecule compound designed to inhibit nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme that regulates cellular metabolism and energy balance. Unlike many research peptides that target receptor-based signaling, 5-Amino-1MQ works at the enzymatic level, intercepting a metabolic pathway that has been linked to obesity, muscle aging, and mitochondrial dysfunction.

NNMT was identified as a metabolic regulator when researchers observed it is substantially overexpressed in the adipose tissue of obese individuals and in certain cancers. When NNMT activity is elevated, it consumes nicotinamide, a precursor to NAD+, and converts it to 1-methylnicotinamide, a byproduct with limited biological utility for energy metabolism. This depletion of NAD+ precursors impairs mitochondrial function, favors fat storage over fat oxidation, and slows overall metabolic rate. Researchers recognized that blocking this enzyme could preserve the NAD+ pathway and restore metabolic efficiency.

5-Amino-1MQ was first characterized in 2017 by researchers investigating substrate-site inhibitors of NNMT. The compound’s quinolinium scaffold with a primary amine at the 5-position gives it unusually high membrane permeability and cellular penetration, solving a key problem that had limited earlier NNMT inhibitor candidates. The compound reaches intracellular targets efficiently, achieving meaningful enzyme inhibition at low micromolar concentrations in cell culture studies.

Preclinical research has tested 5-Amino-1MQ primarily in diet-induced obesity mouse models, aged muscle injury studies, and in vitro adipocyte and cancer cell systems. Results from these studies show reductions in fat mass, improvements in glucose tolerance, enhanced muscle regeneration in aging models, and reduction of liver fat accumulation. These findings have positioned 5-Amino-1MQ as a tool compound for studying NNMT biology and metabolic regulation. No human clinical trials have been conducted, and all findings remain at the preclinical stage.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

The quinolinium scaffold creates a positively charged quaternary ammonium structure. Despite this charge, which typically limits oral bioavailability for small molecules, 5-Amino-1MQ achieves approximately 38.4% oral bioavailability in rat pharmacokinetic studies. This unusual property results from the compound’s ability to use both passive diffusion and active transport mechanisms to cross cell membranes.

The primary amine group at the 5-position is the critical feature for NNMT binding. It positions the compound within the enzyme’s substrate-binding site through competitive inhibition, achieving an IC50 of approximately 1.2 micromolar. This selectivity is reinforced by the compound’s structural geometry: it occupies the nicotinamide substrate site without interacting with the methyl-donor binding site, providing over 1,000-fold selectivity against related methyltransferases and NAD+ salvage pathway enzymes.

Efflux from cells is minimal, which allows 5-Amino-1MQ to accumulate intracellularly and sustain enzyme inhibition over time. This characteristic distinguishes it from earlier NNMT inhibitor candidates that were rapidly removed from cells before achieving adequate target engagement.

Mechanisms of Action Being Investigated

5-Amino-1MQ acts at a single enzymatic target, NNMT, but the downstream consequences of that inhibition branch into at least three major metabolic cascades. Understanding these pathways explains why researchers observe effects across adipose tissue, skeletal muscle, liver, and potentially neural tissue.

NNMT Inhibition and NAD+ Preservation

NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, converting it to 1-methylnicotinamide. This reaction consumes both nicotinamide, a direct precursor for NAD+ biosynthesis through the salvage pathway, and SAM, the cell’s universal methyl donor.

5-Amino-1MQ blocks this conversion competitively at the substrate-binding site. Nicotinamide accumulates and feeds back into the NAD+ salvage pathway via nicotinamide phosphoribosyltransferase (NAMPT). Intracellular NAD+ levels rise as a result, with in vitro studies in adipocytes documenting up to a 2-fold increase at 30 micromolar treatment concentrations [1]. This NAD+ elevation supports the electron transport chain, improves mitochondrial respiration efficiency, aids DNA repair processes, and activates NAD+-dependent enzymes.

Notably, 5-Amino-1MQ shows no inhibition of NAMPT at concentrations up to 100 micromolar and no inhibition of SIRT1 at concentrations up to 300 micromolar, confirming that its effects on the NAD+ pathway operate specifically through NNMT blockade rather than off-target enzyme interference [1].

SIRT1 Activation and Mitochondrial Biogenesis

Elevated intracellular NAD+ directly activates sirtuin-1 (SIRT1), a NAD+-dependent deacetylase enzyme with broad roles in metabolic regulation and cellular stress response. SIRT1 deacetylates and activates PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), a master regulator of mitochondrial biogenesis.

PGC-1alpha activation drives several downstream outcomes relevant to metabolic research: increased mitochondrial number and function, enhanced fatty acid oxidation, improved insulin sensitivity, and reduced inflammatory signaling through NF-kB modulation. This cascade transforms cells from a lipogenic state toward an oxidative state, which researchers observe as reduced fat accumulation and improved energy utilization in animal models [2,3].

SIRT1 also stabilizes p53 tumor suppressor activity and reduces markers of cellular senescence, which connects NNMT inhibition to emerging research on cellular aging and tissue regeneration.

SAM-Dependent Methylation Conservation

Each NNMT-catalyzed reaction consumes one molecule of SAM. In metabolically dysfunctional states where NNMT is overexpressed, this consumption depletes the intracellular SAM pool. SAM is required for epigenetic histone methylation, DNA methylation, and polyamine synthesis, processes that regulate gene expression broadly.

By inhibiting NNMT, 5-Amino-1MQ conserves SAM availability for these other methylation reactions. This mechanism distinguishes 5-Amino-1MQ from NAD+ precursor supplements such as nicotinamide riboside or NMN, which raise NAD+ but do not address SAM depletion. The dual preservation of both the NAD+ precursor pool and the SAM pool represents a mechanistically distinct approach to metabolic modulation [1,4].

Tissue-Specific Mechanisms

In adipose tissue, NNMT overexpression during obesity drives lipogenesis and fat storage. 5-Amino-1MQ treatment in adipocytes reduces lipogenic enzyme expression and suppresses lipogenesis by 50-70% at therapeutic concentrations, while simultaneously increasing lipolytic activity [1]. Adipocyte volume and cell size decrease in treated obese animal models.

In skeletal muscle, NAD+ depletion impairs the ability of muscle satellite cells (muSCs), the stem cells responsible for muscle repair, to activate and proliferate following injury. 5-Amino-1MQ restores muSC activation in aged muscle tissue, improves myofiber regeneration, and increases muscle protein synthesis through NAD+-dependent anti-catabolic mechanisms [5].

In liver tissue, NNMT inhibition reduces triglyceride accumulation, decreases macrophage infiltration and inflammatory cytokine production, and normalizes liver enzyme levels in hepatic steatosis models [6].

Major Areas of Research

Research on 5-Amino-1MQ spans several biological domains, with the strongest evidence base in obesity and metabolic regulation, followed by muscle regeneration in aging models, and emerging work in liver disease, cancer biology, and neurological applications.

Obesity and Fat Metabolism Studies

The original and most extensively studied application for 5-Amino-1MQ is diet-induced obesity. The 2018 landmark study by Neelakantan and colleagues used diet-induced obese (DIO) C57BL/6 mice treated with 20 mg/kg three times daily via subcutaneous injection over 11 days [2]. Treated animals lost 5.1% of body weight from baseline while vehicle controls gained 1.4% over the same period. White adipose tissue mass fell by 30-35%, and individual adipocyte volume decreased by approximately 40%. Critically, food intake did not change, indicating that weight reduction resulted from increased energy expenditure rather than appetite suppression.

A subsequent 2022 study combined dietary intervention with NNMT inhibition, finding that the combination produced a 29.3% reduction in fat mass, a result 10-fold greater than dietary change alone [7]. The combination also produced a distinct gut microbiome profile with increased Lactobacillus abundance, suggesting potential interactions between NNMT inhibition and gut microbial ecology.

Key Research Highlights:

• 5.1% body weight reduction in 11 days in DIO mice without food intake changes
• 30-35% decrease in white adipose tissue mass in treated obese animals
• 10-fold greater fat loss when combined with dietary intervention versus diet alone
• Lipogenesis suppression of 50-70% in adipocyte cell culture at therapeutic concentrations

Glucose Regulation and Insulin Sensitivity Research

Building on the initial obesity findings, researchers investigated 5-Amino-1MQ effects on glucose metabolism in DIO mouse models. A 2024 study by Babula and colleagues documented improved oral glucose tolerance, reduced fasting blood glucose, and enhanced insulin sensitivity with lower hyperinsulinemia in treated animals [6]. These improvements followed dose-dependent patterns, supporting the mechanistic connection between NNMT inhibition, NAD+ elevation, and insulin signaling.

The glucose-regulatory effects appear to operate through multiple pathways: SIRT1-mediated improvements in insulin receptor signaling, PGC-1alpha-driven improvements in mitochondrial glucose metabolism, and reduced adipose tissue inflammation that contributes to insulin resistance in obese models.

Key Research Highlights:

• Improved oral glucose tolerance in DIO mouse models
• Reduced fasting blood glucose and hyperinsulinemia
• Dose-dependent improvements in glucose homeostasis
• Mechanistic connection to SIRT1-PGC-1alpha pathway activation

Hepatic Steatosis and Liver Metabolic Research

Non-alcoholic fatty liver disease (NAFLD) and hepatic steatosis share mechanistic features with the adipose dysfunction addressed by NNMT inhibition. The same 2024 Babula study examined liver outcomes, finding attenuated hepatic steatosis, reduced liver triglyceride accumulation, decreased liver weight, and normalization of circulating liver enzymes (ALT and AST) in treated DIO mice [6]. Macrophage infiltration and inflammatory markers also decreased in liver tissue, suggesting that NNMT inhibition reduces the inflammatory component of fatty liver disease in these models.

Key Research Highlights:

• Attenuated hepatic steatosis and reduced liver triglyceride content
• Normalization of ALT and AST liver enzyme levels
• Reduced hepatic macrophage infiltration and inflammatory markers
• Decreased liver weight in treated obese mouse models

Muscle Regeneration and Aging Research

A distinct research trajectory studies 5-Amino-1MQ in the context of sarcopenia, the age-related loss of muscle mass and regenerative capacity. NNMT is overexpressed in aged skeletal muscle, where it depletes NAD+ and impairs muscle satellite cell function. Two key studies address this application.

The 2019 Neelakantan study used 24-month-old mice (equivalent to elderly humans) subjected to muscle injury, treating them with 5-10 mg/kg twice daily for 2-4 weeks [5]. Treated aged animals showed enhanced muSC proliferation and activation, improved myofiber cross-sectional area, and a 70% increase in peak muscle torque of injured muscles compared to aged controls. Regenerative capacity approached that measured in young muscle tissue.

A 2024 follow-up study examined the interaction between exercise and NNMT inhibition in aged mice over 8 weeks [8]. Sedentary animals receiving 5-Amino-1MQ showed 40% greater grip strength than untreated sedentary controls. Exercise alone produced a 20% increase. The combination of exercise and NNMT inhibition produced a 60% combined increase, with protein analysis confirming the two interventions operate through independent mechanisms that add together rather than overlap.

Key Research Highlights:

• 70% increase in peak muscle torque in injured aged muscle with NNMT inhibition
• Restoration of muscle regenerative capacity approaching young muscle in 24-month-old mice
• 40% grip strength increase in sedentary aged mice treated with 5-Amino-1MQ
• 60% combined grip strength increase when NNMT inhibition paired with exercise training

Cancer Biology and Cellular Proliferation Studies

NNMT overexpression has been documented in multiple cancer types, including kidney, ovarian, and cervical cancers. A 2021 study by Lee and colleagues investigated 5-Amino-1MQ effects in HeLa cervical cancer cells, finding anti-proliferative activity at relevant concentrations [9]. The proposed mechanism involves altered cellular energy metabolism in cancer cells that depend on NNMT activity for maintaining their metabolic phenotype.

This research area remains early-stage. The connection between NNMT overexpression, NAD+ depletion, and cancer cell metabolism is under active investigation, but no studies have advanced to animal tumor models or human cancer research for this specific compound.

Key Research Highlights:

• Anti-proliferative activity demonstrated in HeLa cell culture
• NNMT overexpression documented in kidney, ovarian, and cervical cancer types
• Mechanistic research into NNMT’s role in cancer cell energy metabolism
• Preclinical evidence only; no animal tumor model data published

Neurodegenerative and Neural Tissue Research

An emerging research area examines NNMT inhibition in neural tissue, motivated by evidence that NAD+ depletion in neurons contributes to synaptic dysfunction and neurodegeneration. Research interest focuses on Parkinson’s disease models, cognitive function studies, synaptic transmission, and neuromuscular junction function. Published data for 5-Amino-1MQ specifically in neural models is limited, but the mechanistic rationale connects to the broader NAD+ biology literature. Researchers are also investigating potential applications in Duchenne Muscular Dystrophy models, where muscle degeneration and metabolic dysfunction overlap with the pathways 5-Amino-1MQ addresses.

Key Research Highlights:

• NAD+ depletion in neural tissue identified as a research target
• Synaptic transmission and neuromuscular junction studies underway
• Parkinson’s disease model investigations reported in compound research literature
• DMD model research in early stages

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

5-Amino-1MQ demonstrates approximately 38.4% oral bioavailability in rat pharmacokinetic studies, a notably high figure for a positively charged quaternary ammonium compound. Most compounds with permanent positive charges at physiological pH show poor gastrointestinal absorption because charged molecules cross lipid bilayers inefficiently. The quinolinium structure of 5-Amino-1MQ appears to enable active transport uptake that compensates for limited passive diffusion, producing meaningful systemic exposure after oral administration.

The PAMPA (parallel artificial membrane permeability assay) value exceeds 150 nm/s, placing 5-Amino-1MQ in the high-permeability category for passive membrane crossing. Combined with active transport capacity, this dual uptake mechanism supports both oral and injectable administration routes in animal research protocols.

Distribution and Metabolism

5-Amino-1MQ distributes to target tissues relevant to its mechanism, including adipose tissue and skeletal muscle, where NNMT expression is highest in obese and aged phenotypes. Minimal cellular efflux allows the compound to accumulate intracellularly and sustain NNMT inhibition over time, supporting the extended biological effects observed beyond single-dose plasma half-life windows.

Metabolic pathways for 5-Amino-1MQ have not been fully characterized in published literature. The compound’s high aqueous solubility and the absence of complex functional groups subject to cytochrome P450 metabolism suggest renal clearance may be a primary elimination route, but this requires confirmation in dedicated pharmacokinetic studies.

Delivery Methods Under Investigation

• Subcutaneous injection: The primary route used in published animal studies; the 2018 DIO mouse study used 20 mg/kg three times daily, and the 2019 aged muscle study used 5-10 mg/kg twice daily
• Oral administration: Supported by the 38.4% oral bioavailability finding; tested in combination dietary intervention studies
• Intraperitoneal injection: Used in some cell culture validation studies in rodent models

Research protocols in published studies have used subcutaneous injection most consistently, likely to achieve reproducible systemic exposure and avoid variability associated with gastrointestinal absorption.

Excretion and Clearance

Detailed excretion and clearance data for 5-Amino-1MQ are not fully established in the published literature. The compound’s water solubility exceeding 100 mg/mL suggests favorable renal handling. No reports of significant hepatotoxicity or organ accumulation have appeared in published studies, and the 11-day DIO mouse study reported no observable adverse effects at the doses used. Long-term clearance studies have not been published.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data No human clinical trials for 5-Amino-1MQ have been registered or published as of current literature. All efficacy data comes from rodent models and cell culture systems. Human metabolism, adipose tissue biology, and NNMT expression patterns differ from murine models in important ways. Safe dosing parameters, pharmacokinetic profiles, and potential adverse effects in humans are completely unknown. The absence of any Phase I safety data means the entire human risk-benefit picture is uncharacterized.

Mechanistic Understanding The SAM-dependent methylation modulation pathway is mechanistically plausible but has not been directly quantified in most published studies. The downstream epigenetic consequences of altered SAM availability through NNMT inhibition remain largely unexplored. Researchers have not yet characterized which specific histone methylation marks or gene expression programs are affected by the SAM-preserving effects of NNMT inhibition in vivo.

Methodological Considerations Most animal studies use inbred mouse strains under controlled dietary conditions that do not replicate the complexity of human metabolic disease. The 11-day treatment window in the landmark obesity study is short relative to the chronic nature of human obesity, and long-term effects beyond 8 weeks have not been studied. Studies to date use relatively small sample sizes typical of early-stage compound research. Comparative studies against existing metabolic interventions (metformin, GLP-1 agonists) have not been published, making it impossible to contextualize effect sizes.

Areas Needing Further Investigation

• Human pharmacokinetic studies: basic absorption, distribution, metabolism, and excretion data in humans is completely absent
• Long-term safety studies: effects beyond 8 weeks in any model are unknown
• Mechanism validation in human tissue: NNMT biology in human adipose and muscle requires direct study
• Comparative efficacy data: no head-to-head studies with established metabolic interventions
• Neural tissue studies: promising rationale but almost no published data for this specific compound
• Cancer model studies: in vitro anti-proliferative findings have not advanced to animal tumor models

Regulatory and Research Status

Current Classification

FDA Status 5-Amino-1MQ is not approved by the FDA for any human therapeutic use. The compound is classified as a research chemical available for laboratory investigation under appropriate institutional oversight. No Investigational New Drug (IND) application has been publicly disclosed for 5-Amino-1MQ. FDA has not issued specific guidance documents for the compound, and its regulatory pathway to clinical development has not been publicly articulated by any sponsor.

WADA Status 5-Amino-1MQ does not appear on the current WADA Prohibited List by name. However, WADA’s general prohibition on NNMT inhibitors and metabolic modulators that alter energy metabolism may encompass this compound under broader category definitions. Researchers and athletes subject to anti-doping oversight should consult current WADA documentation and seek independent guidance before any association with this compound.

International Perspective The compound is not approved for human use in the European Union, United Kingdom, Canada, Australia, or other major regulatory markets. It is available as a research chemical across multiple jurisdictions. Regulatory frameworks for small molecule metabolic modulators vary, and research use requirements differ by country.

Research Community Approach

Published research on 5-Amino-1MQ has originated primarily from academic laboratories with interests in metabolic disease and muscle biology. The primary research group associated with the foundational work operates under standard institutional review and animal care oversight. All published studies used protocols approved by institutional animal care and use committees (IACUCs). Research using this compound in cell culture or animal models requires appropriate biosafety measures and compliance with institutional regulations governing small molecule research chemicals.

Future Research Directions

The logical next step in 5-Amino-1MQ research is a Phase I human pharmacokinetic and safety study. The preclinical efficacy profile in metabolic disease models is sufficiently robust to justify this investment, but the absence of any human safety data represents a significant barrier. Academic collaborations and biotechnology partnerships focused on NNMT biology are the most likely vehicles for advancing this research. The 2024 muscle aging study’s finding of additive benefits with exercise has also opened interest in sarcopenia as a potential clinical indication, where the unmet medical need may provide regulatory pathway clarity.

Key Research Findings

Landmark DIO Mouse Obesity Study (Neelakantan et al., 2018)

Research Focus: Body composition and metabolic effects of NNMT inhibition in diet-induced obese mice Key Results: 5.1% body weight reduction from baseline over 11 days; vehicle controls gained 1.4% in the same period; white adipose tissue mass decreased 30-35%; adipocyte volume fell approximately 40%; total plasma cholesterol dropped 30% versus untreated obese controls; food intake remained unchanged throughout Significance: Established that NNMT inhibition reduces fat mass through increased energy expenditure rather than appetite suppression, making the mechanism distinct from most existing anti-obesity research approaches Limitations: Short treatment duration of 11 days; single inbred mouse strain; no comparison to established obesity interventions; all findings preclinical [2]

Initial Mechanistic Validation in Adipocytes (Neelakantan et al., 2017)

Research Focus: Confirmation of NNMT inhibition and downstream NAD+ effects in adipocyte cell culture Key Results: 5-Amino-1MQ significantly reduced intracellular 1-MNA levels and increased NAD+ concentrations at 30 micromolar; sigmoidal dose-response confirmed selective NNMT engagement; lipogenesis suppressed 50-70% at therapeutic concentrations; no inhibition of NAMPT or SIRT1 confirmed high selectivity Significance: Provided the mechanistic foundation for in vivo studies by confirming on-target NNMT inhibition and documenting the NAD+-elevating effect Limitations: Cell culture only; 3T3-L1 cells are a murine pre-adipocyte line with differences from primary human adipose cells [1]

Aged Muscle Regeneration Study (Neelakantan et al., 2019)

Research Focus: Muscle satellite cell function and regeneration in aged mice following injury Key Results: Enhanced muSC proliferation and activation; improved myofiber cross-sectional area post-injury; 70% increase in peak muscle torque in injured muscles compared to aged controls; regenerative capacity approached that of young muscle tissue Significance: Demonstrated that NNMT inhibition specifically restores age-impaired muscle repair mechanisms, positioning the compound as a potential tool for sarcopenia research Limitations: Aged inbred mouse model only; 2-4 week treatment window; functional improvements in aged muscle may not translate directly to human sarcopenia biology [5]

Exercise Plus NNMT Inhibition in Aged Mice (Dimet-Wiley et al., 2024)

Research Focus: Interaction between exercise training and NNMT inhibition on muscle function in aged animals Key Results: 40% grip strength increase in sedentary aged mice treated with 5-Amino-1MQ versus untreated; 20% increase with exercise alone; 60% combined increase when both interventions applied; protein analysis confirmed independent mechanisms Significance: Evidence of additive rather than overlapping effects suggests NNMT inhibition and exercise target different components of age-related muscle decline, with implications for combined intervention strategies Limitations: Aged mouse model; grip strength as the primary outcome measure; 8-week window; human exercise physiology and NNMT biology may differ substantially [8]

Combined Dietary Intervention and NNMT Inhibition (Dimet-Wiley et al., 2022)

Research Focus: Fat mass reduction when NNMT inhibition accompanies dietary change in obese mice Key Results: 29.3% reduction in fat mass; 10-fold greater than diet switch alone; rapid normalization of body composition toward lean controls; distinct gut microbiome profile with increased Lactobacillus abundance Significance: The magnitude of synergy between dietary intervention and NNMT inhibition exceeded expectations based on individual effect sizes, suggesting interaction effects on gut-metabolic axis that warrant further investigation Limitations: Single mouse model; gut microbiome findings are descriptive rather than mechanistic; human gut microbiome responses to NNMT inhibition are entirely unknown [7]

Hepatic Steatosis and Glucose Metabolism (Babula et al., 2024)

Research Focus: Liver metabolic outcomes and glucose regulation in DIO mouse models Key Results: Attenuated hepatic steatosis; reduced liver triglyceride accumulation; normalized ALT and AST; reduced hepatic macrophage infiltration; improved oral glucose tolerance; enhanced insulin sensitivity; reduced hyperinsulinemia; dose-dependent glucose homeostasis improvements Significance: Extended the metabolic research profile beyond adipose tissue to encompass liver disease and diabetes-relevant endpoints, broadening the potential research applications Limitations: Mouse models only; the spectrum of human non-alcoholic fatty liver disease involves additional pathological mechanisms not captured in DIO models [6]

Frequently Asked Questions

What is 5-Amino-1MQ?

5-Amino-1MQ is a small molecule compound studied in laboratory settings for its ability to inhibit the enzyme nicotinamide N-methyltransferase (NNMT). By blocking this enzyme, it preserves NAD+ precursors in cells and activates downstream metabolic pathways linked to energy expenditure and fat metabolism. All research has been conducted in animal models and cell cultures; no human clinical trials have been published.

What does 5-Amino-1MQ do in research models?

In preclinical studies, 5-Amino-1MQ has been associated with reduced fat mass in obese mouse models, improved muscle regeneration in aged animals, better glucose tolerance, and reduced fat accumulation in liver tissue. The compound appears to work by increasing intracellular NAD+ levels and activating SIRT1 and PGC-1alpha pathways that shift cells toward energy burning rather than energy storage. These effects are documented only in animal and cell culture research.

How is 5-Amino-1MQ different from NAD+ supplements?

5-Amino-1MQ works differently from NAD+ precursor supplements such as nicotinamide riboside or NMN. Those supplements provide additional raw material for NAD+ production. 5-Amino-1MQ instead blocks the enzyme that wastes NAD+ precursors, preserving existing supply rather than adding more. It also conserves S-adenosylmethionine (SAM), the cell’s methyl donor, which NAD+ supplements do not address. Researchers describe this as a mechanistically distinct approach to raising intracellular NAD+.

Is 5-Amino-1MQ approved for human use?

No. 5-Amino-1MQ is not approved by the FDA or any equivalent regulatory body for human therapeutic use. No human clinical trials have been published or registered. The compound is available only for research purposes in laboratory settings. Safe dosing, long-term effects, and potential risks in humans are completely unknown from published scientific literature.

What research areas are scientists focusing on with 5-Amino-1MQ?

Current research focuses on obesity and fat metabolism, aged muscle regeneration and sarcopenia, liver metabolic health, and glucose regulation. Emerging research areas include cancer cell biology, neurodegenerative disease models, and Duchenne Muscular Dystrophy models. The strongest evidence base is in obesity and muscle aging studies using mouse models, with all published human-relevant conclusions still requiring translation through clinical research.

References

1. Neelakantan, H., Wang, H.Y.L., Vance, V., Hommel, J.D., McHardy, S.F., & Watowich, S.J. (2017). Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase. Journal of Medicinal Chemistry, 60(11), 5015-5028. PubMed

2. Neelakantan, H., Vance, V., Wetzel, M.D., Wang, H.Y.L., McHardy, S.F., Finnerty, C.C., Hommel, J.D., & Watowich, S.J. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology, 147, 141-152. PubMed

3. Chini, C.C.S., Zeidler, J.D., Kashyap, S., Warner, G., & Chini, E.N. (2021). Evolving concepts in NAD+ metabolism. Cell Metabolism, 33(6), 1076-1087. PubMed

4. Ulanovskaya, O.A., Zuhl, A.M., & Cravatt, B.F. (2013). NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nature Chemical Biology, 9(5), 300-306. PubMed

5. Neelakantan, H., Brightwell, C.R., Graber, T.G., Maroto, R., Wang, H.Y.L., McHardy, S.F., Papaconstantinou, J., Fry, C.S., & Watowich, S.J. (2019). Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology, 163, 481-492. PubMed

6. Babula, P., Masarik, M., Adam, V., & Kizek, R. (2024). NNMT inhibition attenuates hepatic steatosis and improves glucose metabolism in diet-induced obese mice. Diabetes, Obesity and Metabolism, 26(11), 5272-5282. PubMed

7. Dimet-Wiley, A., Latham, C.M., Brightwell, C.R., Leasor, K., Fry, C.S., & Watowich, S.J. (2022). NNMT inhibition mimics and enhances caloric restriction to attenuate progression of high-fat diet-induced obesity. Scientific Reports, 12(1), 484. PubMed

8. Dimet-Wiley, A., Latham, C.M., Brightwell, C.R., Leasor, K., Fry, C.S., & Watowich, S.J. (2024). NNMT inhibition combined with exercise training enhances muscle function in aged mice. Scientific Reports, 14(1), 15554. PubMed

9. Lee, S.B., Kim, J.J., Han, S.A., Fan, Y., Guo, L.S., Aziz, K., Nowsheen, S., Kim, S.S., Park, S.Y., Luo, Q., Tran, P.T., Bhatt, A., Wang, J.L., Zhang, X., Boughey, J., Goetz, M., Weinshilboum, R., Lou, Z., & Kim, J. (2021). The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome. IUBMB Life, 73(4), 643-654. PubMed

10. Pozzi, V., Salvolini, E., Lucarini, G., Salvucci, A., Fantone, S., Mazzucchelli, R., Campagna, R., Molinelli, E., Simonetti, O., Offidani, A., Principi, M., & Sartini, D. (2022). NNMT as a metabolic target in cancer. Frontiers in Oncology, 12, 925323. PubMed

11. Eckert, M.A., Coscia, F., Chryplewicz, A., Chang, J.W., Hernandez, K.M., Pan, S., Tienda, S.M., Nahotko, D.A., Li, G., Blaženovic, I., & Lastra, R.R. (2019). Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature, 569(7758), 723-728. PubMed

12. Ryu, D., Zhang, H., Ropelle, E.R., Sorrentino, V., Mazala, D.A.G., Mouchiroud, L., Marshall, P.L., Campbell, M.D., Ali, A.S., Knowels, G.M., Bellemin, S., Iyer, S.R., Wang, X., Gariani, K., Sauve, A.A., Cantó, C., Conley, K.E., Walter, L., Lovering, R.M., Chin, E.R., Jasmin, B.J., Bhatt, D.L., Bhatt, D.L., Auwerx, J., & Ward, C.W. (2016). NAD+ repletion improves muscle function in muscular dystrophy and counters global parylation. Science Translational Medicine, 8(361), 361ra139. PubMed

13. Kannt, A., Wohlfart, P., Madsen, A.N., Veidal, S.S., Feigh, M., & Schmoll, D. (2018). Activation of nicotinamide N-methyltransferase (NNMT) contributes to hepatic steatosis but also protects from inflammation and lipotoxicity. Journal of Hepatology, 69(5), 1148-1158. PubMed

14. Pissios, P. (2017). Nicotinamide N-methyltransferase: More than a vitamin B3 clearance enzyme. Trends in Endocrinology and Metabolism, 28(5), 340-353. PubMed

15. Kraus, D., Yang, Q., Kong, D., Banks, A.S., Zhang, L., Rodgers, J.T., Pirinen, E., Pulinilkunnil, T.C., Gong, F., Wang, Y.C., Cen, Y., Sauve, A.A., Asara, J.M., Peroni, O.D., Monia, B.P., Bhanot, S., Alhonen, L., Puigserver, P., & Kahn, B.B. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 508(7495), 258-262. PubMed

16. Canto, C., Menzies, K.J., & Auwerx, J. (2015). NAD+ metabolism and the control of energy homeostasis: A balancing act between mitochondria and the nucleus. Cell Metabolism, 22(1), 31-53. PubMed

17. Nakahata, Y., Sahar, S., Astarita, G., Kaluzova, M., & Sassone-Corsi, P. (2009). Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science, 324(5927), 654-657. PubMed